I, being under the age of 30, have a ~80% chance of making it to LEV in my lifespan, with an approximately 5% drop for every additional decade older you are at the present.
You, being a relatively wealthy person in a modernized country? Do you think you’ll be able to afford the LEV by that time, or only that some of the wealthiest people will?
I’m a doctor in India right now, and will likely be a doctor in the UK by then, assuming I’m not economically obsolete. And yes, I expect that if we do have therapies that help provide LEV, they will be affordable in my specific circumstances as well as most LW readers, if not globally. UK doctors are far poorer compared to the their US kin.
Most biological therapies are relatively amenable to economies of scale, and while there are others that might be too bespoke to manage the same, that won’t last indefinitely. I can’t imagine anything with as much demand as a therapy that is proven to delay aging nigh indefinitely, for an illustrative example look at what Ozempic and Co are achieving already, every pharma industry leader and their dog wants to get in on the action, and the prices will keep dropping for a good while.
It might even make economic sense for countries to subsidize the treatment (IIRC, it wouldn’t take much more for GLP-1 drugs to reach the point where they’re a net savings for insurers or governments in terms of reducing obesity related health expenditures). After all, aging is why we end up succumbing to so many diseases in our senescence, not the reverse.
Specifically, gene therapy will likely be the best bet for scaling, if a simple drug doesn’t come about (seems unlikely to me, I doubt there’s such low hanging fruit, even if the net result of LEV might rely on multiple different treatments in parallel with none achieving it by themself).
You, being a relatively wealthy person in a modernized country? Do you think you’ll be able to afford the LEV by that time, or only that some of the wealthiest people will?
I’m a doctor in India right now, and will likely be a doctor in the UK by then, assuming I’m not economically obsolete. And yes, I expect that if we do have therapies that help provide LEV, they will be affordable in my specific circumstances as well as most LW readers, if not globally. UK doctors are far poorer compared to the their US kin.
Most biological therapies are relatively amenable to economies of scale, and while there are others that might be too bespoke to manage the same, that won’t last indefinitely. I can’t imagine anything with as much demand as a therapy that is proven to delay aging nigh indefinitely, for an illustrative example look at what Ozempic and Co are achieving already, every pharma industry leader and their dog wants to get in on the action, and the prices will keep dropping for a good while.
It might even make economic sense for countries to subsidize the treatment (IIRC, it wouldn’t take much more for GLP-1 drugs to reach the point where they’re a net savings for insurers or governments in terms of reducing obesity related health expenditures). After all, aging is why we end up succumbing to so many diseases in our senescence, not the reverse.
Specifically, gene therapy will likely be the best bet for scaling, if a simple drug doesn’t come about (seems unlikely to me, I doubt there’s such low hanging fruit, even if the net result of LEV might rely on multiple different treatments in parallel with none achieving it by themself).